271 related articles for article (PubMed ID: 16798287)
41. Secondary forms of polycystic ovary syndrome.
Kaltsas GA; Isidori AM; Besser GM; Grossman AB
Trends Endocrinol Metab; 2004 Jul; 15(5):204-10. PubMed ID: 15223049
[TBL] [Abstract][Full Text] [Related]
42. Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS.
Pizzo A; Laganà AS; Barbaro L
Gynecol Endocrinol; 2014 Mar; 30(3):205-8. PubMed ID: 24351072
[TBL] [Abstract][Full Text] [Related]
43. Comparison of clinical and laboratory characteristics of cases with polycystic ovarian syndrome based on Rotterdam's criteria and women whose only clinical signs are oligo/anovulation or hirsutism.
Hassa H; Tanir HM; Yildiz Z
Arch Gynecol Obstet; 2006 Jul; 274(4):227-32. PubMed ID: 16691383
[TBL] [Abstract][Full Text] [Related]
44. Increased body iron stores of obese women with polycystic ovary syndrome are a consequence of insulin resistance and hyperinsulinism and are not a result of reduced menstrual losses.
Luque-Ramírez M; Alvarez-Blasco F; Botella-Carretero JI; Sanchón R; San Millán JL; Escobar-Morreale HF
Diabetes Care; 2007 Sep; 30(9):2309-13. PubMed ID: 17536071
[TBL] [Abstract][Full Text] [Related]
45. [Polycystic ovary syndrome II. Endocrinology and metabolism].
Ovesen PG; Møller N; Greisen S; Ingerslev HJ
Ugeskr Laeger; 1998 Jan; 160(3):265-9. PubMed ID: 9454394
[TBL] [Abstract][Full Text] [Related]
46. Interrelationship between ultrasonography and biology in the diagnosis of polycystic ovarian syndrome.
Dewailly D; Duhamel A; Robert Y; Ardaens Y; Beuscart R; Lemaitre L; Fossati P
Ann N Y Acad Sci; 1993 May; 687():206-16. PubMed ID: 8323174
[TBL] [Abstract][Full Text] [Related]
47. High-sensitivity troponin-T levels and associated health conditions in 3146 women aged 46.
Ollila MM; Arffman RK; Kaikkonen K; Morin-Papunen L; Junttila J; Piltonen TT
Ann Med; 2023; 55(2):2264340. PubMed ID: 37795692
[TBL] [Abstract][Full Text] [Related]
48. Adolescent polycystic ovary syndrome.
Connor EL
Adolesc Med State Art Rev; 2012 Apr; 23(1):164-77, xii. PubMed ID: 22764561
[TBL] [Abstract][Full Text] [Related]
49. Detection of functional ovarian hyperandrogenism in women with androgen excess.
Ehrmann DA; Rosenfield RL; Barnes RB; Brigell DF; Sheikh Z
N Engl J Med; 1992 Jul; 327(3):157-62. PubMed ID: 1319000
[TBL] [Abstract][Full Text] [Related]
50. Cardiometabolic abnormalities in the polycystic ovary syndrome: pharmacotherapeutic insights.
Westerveld HE; Hoogendoorn M; de Jong AW; Goverde AJ; Fauser BC; Dallinga-Thie GM
Pharmacol Ther; 2008 Sep; 119(3):223-41. PubMed ID: 18602948
[TBL] [Abstract][Full Text] [Related]
51. [Different types of menstrual cycle and their significance in Chinese women diagnosed with polycystic ovary syndrome according to the Rotterdam consensus criteria].
Xu XH; Tan YC; Shi YH; Wang B; Ju XQ; Zheng QM; Hao CF; Chen ZJ
Zhonghua Yi Xue Za Zhi; 2009 Oct; 89(37):2604-6. PubMed ID: 20137675
[TBL] [Abstract][Full Text] [Related]
52. [Current diagnosis of polycystic ovary syndrome: expanding the phenotype but generating new questions].
Merino P; Schulin-Zeuthen C; Codner E
Rev Med Chil; 2009 Aug; 137(8):1071-80. PubMed ID: 19915773
[TBL] [Abstract][Full Text] [Related]
53. Diagnosis of polycystic ovary syndrome: from NIH criteria to ESHRE-ASRM guidelines.
Carmina E
Minerva Ginecol; 2004 Feb; 56(1):1-6. PubMed ID: 14973405
[TBL] [Abstract][Full Text] [Related]
54. Pharmacologic treatment of polycystic ovary syndrome.
Ehrmann DA; Rychlik D
Semin Reprod Med; 2003 Aug; 21(3):277-83. PubMed ID: 14593550
[TBL] [Abstract][Full Text] [Related]
55. Polycystic Ovary Syndrome in Adolescents: Which MR Imaging-based Diagnostic Criteria?
Fondin M; Rachas A; Huynh V; Franchi-Abella S; Teglas JP; Duranteau L; Adamsbaum C
Radiology; 2017 Dec; 285(3):961-970. PubMed ID: 28742467
[TBL] [Abstract][Full Text] [Related]
56. Diagnosis, phenotype, and prevalence of polycystic ovary syndrome.
Carmina E; Azziz R
Fertil Steril; 2006 Jul; 86 Suppl 1():S7-8. PubMed ID: 16798288
[TBL] [Abstract][Full Text] [Related]
57. Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity.
Ibáñez L; de Zegher F
J Clin Endocrinol Metab; 2004 Apr; 89(4):1592-7. PubMed ID: 15070917
[TBL] [Abstract][Full Text] [Related]
58. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome.
Barber TM; Wass JA; McCarthy MI; Franks S
Clin Endocrinol (Oxf); 2007 Apr; 66(4):513-7. PubMed ID: 17371468
[TBL] [Abstract][Full Text] [Related]
59. Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia.
Genazzani AD; Lanzoni C; Ricchieri F; Baraldi E; Casarosa E; Jasonni VM
Gynecol Endocrinol; 2007 Mar; 23(3):146-52. PubMed ID: 17454168
[TBL] [Abstract][Full Text] [Related]
60. [Diagnosis of polycystic ovary syndrome].
Belosi C; Giuliani M; Suriano R; Sagnella F; Lanzone A
Minerva Ginecol; 2004 Feb; 56(1):7-13. PubMed ID: 14973406
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
